Latest news
25 items- 13D/GSEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)SC 13D/A - Strongbridge Biopharma plc (0001634432) (Subject)
- INSIDERSEC Form 4: Cdk Associates, L.L.C. disposed of 8,060,682 units of Ordinary Shares4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- 13D/GSEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)SC 13D/A - Strongbridge Biopharma plc (0001634432) (Subject)
- SECSEC Form 15-12B filed by Strongbridge Biopharma plc15-12B - Strongbridge Biopharma plc (0001634432) (Filer)
- SECSEC Form EFFECT filed by Strongbridge Biopharma plcEFFECT - Strongbridge Biopharma plc (0001634432) (Filer)
- SECSEC Form EFFECT filed by Strongbridge Biopharma plcEFFECT - Strongbridge Biopharma plc (0001634432) (Filer)
- SECSEC Form EFFECT filed by Strongbridge Biopharma plcEFFECT - Strongbridge Biopharma plc (0001634432) (Filer)
- INSIDERSEC Form 4: Wilhoit Scott L. returned 109,510 units of Ordinary Shares to the company, closing all direct ownership in the company4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Kollender Richard S returned 234,229 units of Ordinary Shares to the company, closing all direct ownership in the company4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Cohen Fredric J. returned 160,408 units of Ordinary Shares to the company, decreasing direct ownership by 50% to 160,408 units4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Johnson John returned 610,092 units of Ordinary Shares to the company, closing all direct ownership in the company4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Steineger Hilde H returned 64,258 units of Ordinary Shares to the company, closing all direct ownership in the company4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Steen Marten returned 64,151 units of Ordinary Shares to the company4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Sherman Jeffrey W returned 64,258 units of Ordinary Shares to the company, closing all direct ownership in the company4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Kong Garheng returned 63,993 units of Ordinary Shares to the company, closing all direct ownership in the company4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Gill David N returned 78,058 units of Ordinary Shares to the company, closing all direct ownership in the company4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Long Stephen J returned 117,793 units of Ordinary Shares to the company, closing all direct ownership in the company4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Wilhoit Scott L. covered exercise/tax liability with 27,515 units of Ordinary Shares, decreasing direct ownership by 20% to 109,510 units4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Long Stephen J covered exercise/tax liability with 49,307 units of Ordinary Shares, decreasing direct ownership by 30% to 117,793 units4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Kollender Richard S covered exercise/tax liability with 64,791 units of Ordinary Shares, decreasing direct ownership by 22% to 234,229 units4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Cohen Fredric J. covered exercise/tax liability with 51,548 units of Ordinary Shares, decreasing direct ownership by 24% to 160,408 units4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Steen Marten covered exercise/tax liability with 17,763 units of Ordinary Shares4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Johnson John covered exercise/tax liability with 334,868 units of Ordinary Shares, decreasing direct ownership by 35% to 610,092 units4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Steineger Hilde H covered exercise/tax liability with 17,763 units of Ordinary Shares, decreasing direct ownership by 22% to 64,258 units4 - Strongbridge Biopharma plc (0001634432) (Issuer)
- INSIDERSEC Form 4: Sherman Jeffrey W covered exercise/tax liability with 17,763 units of Ordinary Shares, decreasing direct ownership by 22% to 64,258 units4 - Strongbridge Biopharma plc (0001634432) (Issuer)
SBBP FAQ
6 questionsWhat does Strongbridge Biopharma plc do?
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II...Where does SBBP stock trade?
Strongbridge Biopharma plc (SBBP) is listed on NASDAQ.What sector and industry is SBBP in?
Strongbridge Biopharma plc operates in the Health Care sector, Major Pharmaceuticals industry.When did Strongbridge Biopharma plc go public?
Strongbridge Biopharma plc (SBBP) completed its IPO in 2015.What companies are similar to SBBP?
Notable peers in the same industry include DRNA (Dicerna Pharmaceuticals, Inc.), TRIL (Trillium Therapeutics Inc.), KDMN (Kadmon Holdings, Inc.), FLXN (Flexion Therapeutics, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.). Compare SBBP side-by-side with any of them on Quantisnow.How can I track SBBP on Quantisnow?
Quantisnow aggregates Strongbridge Biopharma plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SBBP to receive live email and push alerts on every new disclosure.